HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Revolution Medicines and Summit Therapeutics to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors July 1, 2025
Sanofi to advance Kymera’s next-gen oral IRAK4 degrader KT-485 into clinical testing and will not advance KT-474 July 1, 2025
Hummingbird Bioscience Licenses HMBD-002, Ph 2-Ready Anti-VISTA Monoclonal Antibody, to Percheron Therapeutics July 1, 2025
Revolution Medicines and Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for RAS-Addicted Cancers July 1, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders July 1, 2025
Xcell Biosciences and Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies July 1, 2025
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers June 25, 2025
Orion and Glykos announce the extension of research collaboration and licensing agreement for the development of next-gen ADCs June 24, 2025
Marker Therapeutics and Cellipont Bioservices to Advance cGMP Manufacturing of MT-601 for Patients with Lymphoma June 24, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel ADC Targeting CDH6 June 24, 2025
Enterome raises $19M to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma June 24, 2025
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies June 24, 2025
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3 to RayzeBio, a BMS Company, for a potential value of up to $1.35B plus royalties June 17, 2025
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel CDH6-targeting ADC June 17, 2025
